Preemption, tort reform, and pharmaceutical claims: part two: has the Food and Drug Administration shown it is solely Responsible for the protection of patients? Can it do so? Will it do so?(Medicolegal Issues)

From: Baylor University Medical Center Proceedings | Date: January 1, 2008| Author: Thornton, Russell G. | Copyright information

There should be no question that adverse drug events are a significant issue. A recent report indicated that in 2005 there were 89,842 serious adverse drug-related events (1), and 15,107 of these adverse events were deaths (1). In 2002, adverse drug events were associated with more than 3 million hospital admissions and increased the US hospitalization bill by $17 billion (2). Non-hospitalization-related medication injuries cost $76.6 billion (2). Data show that 3% to 4% of medicat...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

The side effects of side effects: the recent Institute of Medicine report pointed its institutional finger at the FDA over a variety of shortcomings surrounding drug safety post-marketing surveillance. Warren Ross reports on the potential ramifications for the pharmaceutical industry.
Medical Marketing & Media ; The pharmaceutical industry thrives on side effects. At first glance, that might seem like a flat contradiction of the facts. Think Vioxx--was that withdrawal good for Merck? Of course not. But it was good for manufacturers with safer NSAIDS. In fact, the development of products with better safety
REPORT FAULTS FDA DRUG-SAFETY UNIT
The Boston Globe ; WASHINGTON The Food and Drug Administration's office responsible for policing the safety of prescription drugs is underfunded, understaffed, and lacks a "clear and effective" process for deciding whether and how to act when it determines a drug is unsafe, federal investigators said yesterday. A
IoM drug safety study may buy time for FDA; report will play in PDUFA IV.(Regulatory Update)
Pharmaceutical Processing ; FDA's decision to proceed with an Institute of Medicine review of drug safety regulation could trigger a full-fledged debate over the possibility of creating a separate post-marketing regulatory agency in the U.S. FDA expects IoM to examine the possibility of creating a separate entity to oversee
Congressional hearing examines ways to bolster drug safety through FDA.(Practice Trends)
Family Practice News ; WASHINGTON -- Congress is considering giving the Food and Drug Administration more authority over the pharmaceutical companies it deals with, but some legislators are warning against doing too much too fast. Changes to drug safety must be carefully considered to make sure they don't unduly impact
FDA Plans New Board To Monitor Drug Safety; Independent Panel to Be More Open to the Public
The Washington Post ; The Food and Drug Administration will create an independent board to more aggressively monitor the safety of drugs on the market as part of an effort to restore public confidence in the nation's prescription drug supply, Health and Human Services Secretary Mike Leavitt announced yesterday. "The
Report Faults FDA on Drug Safety
The Washington Post ; Five experts who have advised the Food and Drug Administration on drug safety yesterday threw their weight behind mounting criticism that the agency does not adequately protect the public from unsafe drugs. The experts, all current or former members of the agency's Drug Safety and Risk Management
Hearing examines ways to bolster drug safety: Congress considering boosting FDA's authority; agency would have more clout over product labeling.(Practice Trends)
Skin & Allergy News ; WASHINGTON -- Congress is considering giving the Food and Drug Administration more authority over the pharmaceutical companies it deals with, but some legislators are warning against doing too much too fast. Changes to drug safety must be carefully considered to make sure they don't unduly impact
FDA hampered in drug safety program monitoring
Lawyers USA ; Lack of clear regulatory authority and chronic underfunding at the Food and Drug Administration are among the problems hampering the agency's ability to monitor its post-market drug safety program, according to a recent report released by the Institute of Medicine. The study was released as part of
FDA seeking proposals to improve drug safety.(Practice Trends)
Family Practice News ; Washington -- Acknowledging that its drug safety system is inadequate, several Food and Drug Administration officials told an Institute of Medicine panel examining the issue that the agency is ready for recommendations on how to better protect the public's health. The IOM committee was convened at
FDA seeks right person to monitor drug safety.(Food and Drug Administration)(Brief Article)
Chain Drug Review ; WASHINGTON -- The Food and Drug Administration has launched a nationwide search for its director of drug safety. The person selected for this job will be in the center of critical issues facing the nation on the safe and appropriate use of medications, and will have a profound impact on the future